- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00260208
Liver Fibrosis in Patients Transplanted for Hepatitis C Receiving Either Cyclosporine Microemulsion or Tacrolimus
A Multicenter, Randomized, Open-label Study to Compare the Development of Liver Fibrosis at 12 Months After Transplantation for Hepatitis C Cirrhosis in Patients Receiving Either Cyclosporine Microemulsion or Tacrolimus
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Zurich, Switzerland, 8091
- Novartis Investigational site
-
-
-
-
New Jersey
-
East Hanover, New Jersey, United States
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria
- Reason for transplant is end-stage liver disease due to hepatitis C cirrhosis
- Patients receiving a first liver transplant from a deceased or living donor
- Patients in whom biopsies will be possible
Exclusion criteria
- Recipients of a liver from an hepatitis C virus positive (HCV+), human immunodeficiency virus positive (HIV+) or hepatitis B virus positive (HBV+) donor
- Patients with any severe coexisting disease or suffering any unstable medical condition or co-infected with HBV or HIV
- Patients with co-existing alcoholic disease who have not been abstinent for at least 6 months
- Transplanted for liver cancer exceeding a pre-defined size
- Pregnant or nursing women
Other protocol-defined inclusion/exclusion criteria may apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Cyclosporin A
The first administration of Cyclosporin A (CsA) was within the first 24 hours post-transplantation at an initial dose of 10-15mg/kg/day either orally, via a nasogastric (NG) tube or intravenously (i.v). Twice daily (b.i.d.) administration was maintained throughout the study period. During the study, the dose of CsA was adjusted, as necessary, to achieve and maintain the C2 or C0 blood CsA concentration within the target ranges. Before enrolling the first patient, each center chose the adjunct immunosuppressive (IS) regimen between:
The regimen selected by the center was to be given to all patients enrolled in the trial from this center. |
Initial dose of 10-15mg/kg/day either orally, via a nasogastric (NG) tube or intravenously (i.v.) within the first 24 hours post-transplantation.
Other Names:
|
Active Comparator: Tacrolimus
Tacrolimus was administered within the first 24 hours post-transplantation at an initial dose of 0.1-0.15 mg/kg/day in 2 divided doses (twice daily at 12-hour interval) either orally or via a nasogastric (NG) tube or intravenously (i.v). Twice daily (b.i.d.) administration was maintained throughout study period. Throughout the study, the dose of tacrolimus was adjusted as necessary to achieve and maintain C0 tacrolimus concentrations within target ranges. Before enrolling the first patient, each center chose adjunct immunosuppressive (IS) regimen between:
The regimen selected by center was to be given to all patients enrolled in trial from this center. |
Tacrolimus was administered within the first 24 hours post-transplantation at an initial dose of 0.1-0.15
mg/kg/day in 2 divided doses either orally or via a nasogastric (NG) tube or intravenously (i.v).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Fibrosis Score 2 or Above [Ishak-Knodell Fibrosis Score (FS) ≥ 2] Within 1 Year Post-transplant
Time Frame: 1 year post-transplant
|
Assessment of hepatic fibrosis was performed with liver biopsies at Day 1, Month 6, 12 and 24, read centrally by two independent pathologists blinded to treatment arm and time of biopsy.
Ishak-Knodell score was used to stage liver disease; 0= None; 1= Portal fibrosis (some); 2= Portal fibrosis (most); 3= Bridging fibrosis (few); 4= Bridging fibrosis (many); 5 = Incomplete cirrhosis; 6 = Cirrhosis.
Higher score indicates greater fibrosis.
Logistic regression on the presence of IK>=2 was applied based on central biopsy readings only.
|
1 year post-transplant
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Combined Endpoint of Death or Graft Loss or Fibrosis Score (FS) ≥ 2
Time Frame: 1 year post-transplant
|
The number of participants with combined end point of death or graft loss or presented with a Ishak-Knodell fibrosis score (FS) ≥2 was calculated.
Graft loss was considered to have occurred when allograft was presumed to be lost if a patient had liver retransplant or died.
Assessment of hepatic fibrosis was performed with liver biopsies read centrally.
Ishak-Knodell FS was used to stage liver disease; 0=none; 1=portal fibrosis (some); 2=portal fibrosis (most); 3=bridging fibrosis (few); 4=bridging fibrosis (many); 5=Incomplete cirrhosis; 6=cirrhosis.
Higher score indicates greater fibrosis.
|
1 year post-transplant
|
Number of Participants With Fibrosing Cholestatic Hepatitis
Time Frame: 1 year post-transplantation
|
Fibrosing cholestatic hepatitis (FCH) is characterized by progressive jaundice with a rapid decline in liver function leading to liver failure, most often associated with markedly elevated viral levels detected in the bloodstream (e.g. more than 20 times pre-liver transplantation levels) and in the liver tissue as well.
The presence of FCH was reported based on the diagnosis given by the investigator.
|
1 year post-transplantation
|
Number of Participants With Death, Graft Loss, Death or Graft Loss, Graft Loss With Re-transplantation
Time Frame: 1 year post-transplant
|
Graft loss was considered to have occurred when allograft was presumed to be lost if a patient had a liver re-transplant or died.
|
1 year post-transplant
|
Number of Participants With Treated Acute Rejection, Biopsy Proven Acute Rejection (BPAR), and Sub-clinical Rejection
Time Frame: 1 year post-transplant
|
Treated acute rejection is defined as an acute rejection, clinically suspected, whether biopsy-proven or not, which has been treated and confirmed by the investigator according to the response to therapy.
BPAR was defined as a treated acute rejection confirmed by biopsy.
The local pathologist graded biopsies according to the Banff (1997) criteria.
A sub-clinical rejection was defined as a rejection identified by center driven biopsy, i.e. a biopsy performed routinely at some pre-defined time points after transplantation as per center practice in the absence of any clinical signs of rejection.
|
1 year post-transplant
|
Number of Participants With Combined Endpoint of Death or Graft Loss or Biopsy Proven Acute Rejection (BPAR)
Time Frame: 1 year post-transplant
|
BPAR was defined as a treated acute rejection confirmed by biopsy.
The local pathologist graded biopsies according to the Banff (1997) criteria.
Graft loss was considered to have occurred when allograft was presumed to be lost if a patient had a liver re-transplant or died.
|
1 year post-transplant
|
Number of Participants With Death or Re-transplantation Due to Recurrence of Hepatitis C Cirrhosis
Time Frame: 1 year post-transplant
|
Cirrhosis was resulted due to the recurrence of the hepatitis C virus infection in the transplanted liver.
|
1 year post-transplant
|
Number of Participants With Fibrosis Score 2 or Above [Ishak-Knodell Fibrosis Score (FS) ≥ 2] Within 1 Year Post-transplant (Intent to Treat Population)
Time Frame: 1 year post-transplant
|
Assessment of hepatic fibrosis was performed with liver biopsies at Day 1, Month 6, 12 and 24, read centrally by two independent pathologists blinded to treatment arm and time of biopsy.
Ishak-Knodell score was used to stage liver disease; 0= None; 1= Portal fibrosis (some); 2= Portal fibrosis (most); 3= Bridging fibrosis (few); 4= Bridging fibrosis (many); 5 = Incomplete cirrhosis; 6 = Cirrhosis.
Higher score indicates greater fibrosis.
|
1 year post-transplant
|
Mean Value of Liver Function Tests at 1 Year Post-transplantation
Time Frame: 1 year post-transplant
|
The mean value (in Units per liter, IU/L) of following tests were calculated at 1 year post-transplant:
|
1 year post-transplant
|
Log-transformed Hepatitis C Virus Ribonucleic Acid (HCV RNA) Values up to 1 Year Post Transplant
Time Frame: Pre-transplant (Day 1), Day , Day 8, Day 29, Month 6 and 12 post- transplant
|
HCV RNA was measured (IU/µL)centrally pre-transplant (Day 1) and at 48 hours (Day 3), Day 8 and 29, Month 6 and 12 post-transplant and concomitantly to any additional biopsies performed.
|
Pre-transplant (Day 1), Day , Day 8, Day 29, Month 6 and 12 post- transplant
|
Percentage of Participants With an Increase of at Least 1 Stage in Fibrosis
Time Frame: Between 1 and 2 years
|
Assessment of hepatic fibrosis was performed with liver biopsies at Day 1, Month 6, 12 and 24, read centrally by two independent pathologists blinded to treatment arm and time of biopsy.
Ishak-Knodell score was used to stage liver disease; 0= None; 1= Portal fibrosis (some); 2= Portal fibrosis (most); 3= Bridging fibrosis (few); 4= Bridging fibrosis (many); 5 = Incomplete cirrhosis; 6 = Cirrhosis.
Higher score indicates greater fibrosis.
An increase of at least 1 stage demonstrated a worsening of the disease, i.e. the transition from one score to the next higher one.
|
Between 1 and 2 years
|
Mean Fibrosis Score
Time Frame: At 1and 2 years and its evolution over time
|
Assessment of hepatic fibrosis was performed with liver biopsies at Day 1, Month 6, 12 and 24, read centrally by two independent pathologists blinded to treatment arm and time of biopsy.
Ishak-Knodell score was used to stage liver disease; 0= None; 1= Portal fibrosis (some); 2= Portal fibrosis (most); 3= Bridging fibrosis (few); 4= Bridging fibrosis (many); 5 = Incomplete cirrhosis; 6 = Cirrhosis.
Higher score indicates greater fibrosis.
The mean score was equivalent to mean of IK at 1 and 2 years (evolution over time).
|
At 1and 2 years and its evolution over time
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Flaviviridae Infections
- Hepatitis, Viral, Human
- Enterovirus Infections
- Picornaviridae Infections
- Fibrosis
- Hepatitis
- Hepatitis A
- Hepatitis C
- Liver Cirrhosis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Dermatologic Agents
- Antifungal Agents
- Calcineurin Inhibitors
- Tacrolimus
- Cyclosporine
- Cyclosporins
Other Study ID Numbers
- COLO400A2426
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis C
-
Tripep ABInovio PharmaceuticalsUnknownChronic Hepatitis C Virus InfectionSweden
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsWithdrawnChronic Hepatitis C Virus InfectionIsrael
-
Hadassah Medical OrganizationUnknownChronic Hepatitis C Virus InfectionIsrael
-
AbbVieCompletedChronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 1a
-
AbbVie (prior sponsor, Abbott)CompletedChronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV)United States, Australia, Canada, France, Germany, New Zealand, Puerto Rico, Spain, United Kingdom
-
Trek Therapeutics, PBCCompletedChronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV) | Hepatitis C Viral InfectionUnited States, New Zealand
-
Trek Therapeutics, PBCCompletedChronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 4 | Hepatitis C Viral InfectionUnited States
-
AbbVieCompletedHepatitis C Virus | Chronic Hepatitis C Virus
-
AbbVie (prior sponsor, Abbott)CompletedHepatitis C | Chronic Hepatitis C Infection | HCV | Hepatitis C Genotype 1United States
-
Beni-Suef UniversityCompletedChronic Hepatitis C Virus InfectionEgypt
Clinical Trials on Cyclosporine A
-
AllerganCompletedDry Eye SyndromesUnited States
-
Zambon SpAEnrolling by invitationBronchiolitis Obliterans | Bronchiolitis Obliterans Syndrome | Obliterative BronchiolitisFrance, United States, Spain, Israel, Belgium, Denmark, Germany, United Kingdom, Austria
-
Bing HanCompletedPure Red Cell Aplasia, AcquiredChina
-
University Hospital, RouenCompletedKidney Transplantation | Primary Prevention | Kidney Failure
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedCardiomyopathy, Hypertrophic | Heart HypertrophyUnited States
-
University of Oslo School of PharmacyCompletedHeart Transplantation | Acute Renal FailureNorway
-
University of Oslo School of PharmacyCompletedHeart Transplantation | Renal TransplantationNorway
-
LEO PharmaWithdrawnAtopic DermatitisNetherlands
-
St. Franziskus HospitalCompletedUveitis | Juvenile Idiopathic ArthritisGermany
-
Sirion Therapeutics, Inc.CompletedDry Eye SyndromesUnited States